165 related articles for article (PubMed ID: 26891467)
1. Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I.
Kim SB; Sayeed A; Villalon AH; Shen ZZ; Shah MA; Hou MF; Nguyen Ba D
Asia Pac J Clin Oncol; 2016 Jun; 12(2):125-32. PubMed ID: 26891467
[TBL] [Abstract][Full Text] [Related]
2. Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II.
Kim SB; Sayeed A; Villalon AH; Shen ZZ; Yau TK; Shah MA; Hou MF; Thuan TV; Ba DN; Chao TY
Asian Pac J Cancer Prev; 2016; 17(2):697-702. PubMed ID: 26925666
[TBL] [Abstract][Full Text] [Related]
3. Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II.
Kim SB; Kok YT; Thuan TV; Chao TY; Shen ZZ
J Breast Cancer; 2015 Dec; 18(4):356-64. PubMed ID: 26770242
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study.
Xie H; Liu J; Yu S; Chen Y; Zheng M; Deng Y; Wang S; Jiang J; Li Y; Li H; Kang H; Zhang C; Zhang GJ; Su F; Cheng A; Wang S
Adv Ther; 2019 Jan; 36(1):131-146. PubMed ID: 30511279
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
[TBL] [Abstract][Full Text] [Related]
7. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract][Full Text] [Related]
8. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.
Brain EG; Bachelot T; Serin D; Kirscher S; Graic Y; Eymard JC; Extra JM; Combe M; Fourme E; Noguès C; Rouëssé J;
JAMA; 2005 May; 293(19):2367-71. PubMed ID: 15900007
[TBL] [Abstract][Full Text] [Related]
9. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
[TBL] [Abstract][Full Text] [Related]
10. Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
Yardley DA; Hart L; Waterhouse D; Whorf R; Drosick DR; Murphy P; Badarinath S; Daniel BR; Childs BH; Burris H
Breast Cancer Res Treat; 2013 Dec; 142(3):655-65. PubMed ID: 24253810
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
12. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
15. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.
Seo JH; Sung HJ; Park KH; Choi IK; Oh SC; Shin SW; Kim YH; Kim JS; Kim AR; Lee JB; Koo BH
Invest New Drugs; 2009 Feb; 27(1):67-73. PubMed ID: 18758689
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Nabholtz JM; North S; Smylie M; Mackey J; Au HJ; Au R; Morrish D; Salter E; Tonkin K
Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
